These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 21470023)

  • 21. What primary care providers need to know about preexposure prophylaxis for HIV prevention: a narrative review.
    Krakower D; Mayer KH
    Ann Intern Med; 2012 Oct; 157(7):490-7. PubMed ID: 22821365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intentions to use preexposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants.
    Fuchs JD; Sobieszczyk ME; Madenwald T; Grove D; Karuna ST; Andrasik M; Sherwat A; Broder G; Mayer K; Koblin B; Hammer S;
    J Acquir Immune Defic Syndr; 2013 Jul; 63(3):259-62. PubMed ID: 23614998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness.
    Paltiel AD; Freedberg KA; Scott CA; Schackman BR; Losina E; Wang B; Seage GR; Sloan CE; Sax PE; Walensky RP
    Clin Infect Dis; 2009 Mar; 48(6):806-15. PubMed ID: 19193111
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preexposure prophylaxis for the prevention of HIV transmission to women.
    Aaron E; Cohan D
    AIDS; 2013 Jan; 27(1):F1-5. PubMed ID: 22914582
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching STRATEGIES in HIV treatment.
    Schrijvers R; Debyser Z
    Lancet Infect Dis; 2014 Jul; 14(7):537-40. PubMed ID: 24908549
    [No Abstract]   [Full Text] [Related]  

  • 26. Boosting HIV treatment options: good news, new challenges.
    Cahn P; Sued O
    J Infect Dis; 2013 Jul; 208(1):4-6. PubMed ID: 23532095
    [No Abstract]   [Full Text] [Related]  

  • 27. HIV-serodiscordant couples desiring a child: 'treatment as prevention,' preexposure prophylaxis, or medically assisted procreation?
    Mabileau G; Schwarzinger M; Flores J; Patrat C; Luton D; Epelboin S; Mandelbrot L; Matheron S; Yazdanpanah Y
    Am J Obstet Gynecol; 2015 Sep; 213(3):341.e1-12. PubMed ID: 25979615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
    Anderson PL; Glidden DV; Liu A; Buchbinder S; Lama JR; Guanira JV; McMahan V; Bushman LR; Casapía M; Montoya-Herrera O; Veloso VG; Mayer KH; Chariyalertsak S; Schechter M; Bekker LG; Kallás EG; Grant RM;
    Sci Transl Med; 2012 Sep; 4(151):151ra125. PubMed ID: 22972843
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ethics and pre-exposure prophylaxis for HIV infection.
    Sugarman J; Mayer KH
    J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2(0 2):S135-9. PubMed ID: 23764625
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence.
    McAllister J; Read P; McNulty A; Tong WW; Ingersoll A; Carr A
    HIV Med; 2014 Jan; 15(1):13-22. PubMed ID: 24007390
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abacavir/3TC vs. tenofovir/FTC: interim results from ACTG 5202.
    Albrecht H
    AIDS Clin Care; 2008 Apr; 20(4):28. PubMed ID: 19271262
    [No Abstract]   [Full Text] [Related]  

  • 33. Oral preexposure prophylaxis for HIV--another arrow in the quiver?
    Michael NL
    N Engl J Med; 2010 Dec; 363(27):2663-5. PubMed ID: 21091280
    [No Abstract]   [Full Text] [Related]  

  • 34. Coverage, context and targeted prevention: optimising our impact.
    Aral SO; Cates W
    Sex Transm Infect; 2013 Jun; 89(4):336-40. PubMed ID: 23270932
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Perceptions of emtricitabine-tenofovir in HIV PrEP.
    Kruse L; Stover K; Henderson H
    HIV Clin; 2014; 26(1):1, 4-7. PubMed ID: 24855688
    [No Abstract]   [Full Text] [Related]  

  • 36. Fanconi syndrome-like tubular acidosis associated with a tenofovir-containing antiretroviral regimen in a human immunodeficiency virus-1-infected Asian woman.
    Kiyasu Y; Koganemaru H; Hitomi S
    J Infect Chemother; 2012 Apr; 18(2):255-7. PubMed ID: 21918819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ACOG Committee Opinion no 595: Committee on Gynecologic Practice: Preexposure prophylaxis for the prevention of human immunodeficiency virus.
    Obstet Gynecol; 2014 May; 123(5):1133-1136. PubMed ID: 24785877
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid improvement in fasting lipids and hepatic toxicity after switching from didanosine/lamivudine to tenofovir/emtricitabine in patients with toxicity attributable to didanosine.
    Palacios R; Rivero A; Santos I; Ríos MJ; Castaño M; del Arco A; Santos González J;
    HIV Clin Trials; 2010; 11(2):118-20. PubMed ID: 20542848
    [No Abstract]   [Full Text] [Related]  

  • 39. A 4-drug combination (Stribild) for HIV.
    Med Lett Drugs Ther; 2012 Nov; 54(1404):95-6. PubMed ID: 23183388
    [No Abstract]   [Full Text] [Related]  

  • 40. Antiretrovirals for HIV Exposure Prophylaxis.
    Nikolopoulos G; Tsiodras S; Bonovas S; Hatzakis A
    Curr Med Chem; 2012; 19(35):5924-39. PubMed ID: 22963555
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.